A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Ifetroban (Primary)
- Indications Cardiomyopathies; Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 23 Oct 2019 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 23 Oct 2019 Planned primary completion date changed from 1 May 2021 to 1 Jan 2022.
- 23 Oct 2019 Planned initiation date changed from 1 Nov 2019 to 1 Jan 2020.